CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

In a report released yesterday, Lance Wilkes from Bernstein maintained a Buy rating on Cigna (CI – Research Report), with a price target of ...

Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2024 financial results on Thursday, January ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

Claro Advisors LLC lessened its stake in shares of The Cigna Group (NYSE:CI – Free Report) by 35.9% during the fourth quarter ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration with Progyny, Inc (Nasdaq: PGNY) that makes best-in-class fertility ...